Definitive Healthcare Corp. Files Form 8-K with SEC on March 30, 2026 – Company Details and Filing Information
Definitive Healthcare Corp. (NASDAQ: DH) has filed an 8-K form with the SEC on March 30, 2026, announcing the resignation of Jeff Haywood from its Board of Directors and the Human Capital Management and Compensation Committee. This change is considered significant for the company's corporate governance and investor confidence, though no immediate financial impact was disclosed. The company, incorporated in Delaware, operates in the Services-Prepackaged Software sector and is not classified as an emerging growth company.
Definitive Healthcare director Jeff Haywood resigns from board and committee By Investing.com
Jeff Haywood has resigned from Definitive Healthcare Corp.'s Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations or policies, and consequently, the Board and Compensation Committee sizes have been reduced. This news follows the company's Q4 fiscal 2025 earnings report, which showed mixed results, including exceeding revenue estimates but missing EPS predictions, leading Stephens to lower its price target.
Definitive Healthcare (DH) CEO has RSU shares withheld for taxes
Definitive Healthcare Corp.'s CEO, Kevin Coop, had 37,593 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from RSU vesting. This was a tax-withholding disposition, not an open-market sale, and he now directly holds 5,078,872 shares. The event is considered neutral in terms of market impact and sentiment.
Definitive Healthcare (DH) chair has 45,154 shares withheld for RSU tax obligations
Jason Ronald Krantz, director and executive chairman of Definitive Healthcare Corp. (DH), had 45,154 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from the vesting of Restricted Stock Units (RSUs). This was a tax-withholding disposition by the issuer, not an open-market sale, with the shares valued at $1.09 each. Following this transaction, Krantz directly holds 1,213,604 shares and beneficially owns an additional 450,000 shares through a trust.
Director Jeff Haywood exits Definitive Healthcare (DH) board, shrinking seats
Definitive Healthcare Corp. announced that director Jeff Haywood resigned from its Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations. As a result, the board size decreased from nine to eight members, and the Compensation Committee from three to two members, without immediate replacement.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.37
Definitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.
Definitive Healthcare (DH) price target decreased by 29.12% to 2.82
The article reports that Definitive Healthcare (DH) has had its price target decreased by 29.12% to $2.82. No further details are provided in the snippet.
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Reduce" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Reduce" rating from ten analysts, with an average 12-month target price of $3.52. The stock opened at $1.19, trading significantly below analyst targets and its 200-day simple moving average. Despite the negative sentiment, institutional ownership is high at 98.67%, with firms like Goldman Sachs and AQR notably increasing their stakes.
Definitive Healthcare Corp. (DH) matches Q4 earnings estimates
The article states that Definitive Healthcare Corp. (DH) matched its Q4 earnings estimates. This indicates that the company performed as expected by analysts during the quarter.
Definitive Healthcare stock holds at Neutral as revenue declines persist By Investing.com
BTIG has maintained its Neutral rating on Definitive Healthcare Corp (NASDAQ:DH) following its Q4 fiscal 2025 earnings report. Despite revenue exceeding estimates, the company experienced a 1.2% year-over-year decline in revenue and a 12% decline in remaining performance obligations, with both total and Enterprise customers decreasing sequentially. Although the stock has suffered a significant plunge, InvestingPro analysis suggests it is undervalued and analysts project a return to profitability in 2026.
Tax-withholding share transfer by Definitive Healthcare (DH) CEO Coop
Definitive Healthcare Corp. CEO Kevin Coop had 175,524 Class A shares withheld by the company at $1.28 per share to cover tax withholding obligations related to the vesting and settlement of previously reported Restricted Stock Units (RSUs). This transaction, identified by transaction code F, was not an open-market sale but an administrative measure. Following this tax-related disposition, Coop directly holds 5,116,465 shares of Definitive Healthcare common stock, maintaining a significant stake in the company.
Zacks Research Downgrades Definitive Healthcare (NASDAQ:DH) to Strong Sell
Zacks Research has downgraded Definitive Healthcare (NASDAQ:DH) to a "strong sell" rating. This follows several other analysts' reports, resulting in an overall average rating of "Reduce" and a consensus price target of $3.52. The stock opened at $1.18, trading down 3.3%, with a market capitalization of $166.8 million and primarily institutional ownership.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.14
Definitive Healthcare Corp. has reached a new 52-week low of USD 1.14, representing a 78.12% drop in one-year performance and a significant decline from its 52-week high of USD 4.70. With a market capitalization of USD 214 million, the company exhibits low profitability, a negative debt-to-equity ratio, and no dividend yield, suggesting financial instability and ongoing challenges in the market. Its performance consistently lags behind the S&P 500.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.10
Definitive Healthcare Corp. has reached a new 52-week low of $1.10, with its stock price plummeting 80.51% over the past year. The company, a microcap player in the Software Products industry with a market capitalization of $214 million, displays low valuation metrics including a P/E ratio of 6.00 and a price-to-book ratio of 0.75. Its consistent underperformance against the S&P 500 signals significant financial struggles and a need for strategic reassessment.
Definitive Healthcare (NASDAQ:DH) Stock Rating Lowered by Wall Street Zen
Definitive Healthcare (NASDAQ:DH) has had its stock rating downgraded by Wall Street Zen from a "buy" to a "hold" due to lowered Q1 and full-year 2026 guidance, despite Q4 revenue being in line. The company's profitability metrics deteriorated year-over-year, and several institutional investors have trimmed their positions, indicating reduced confidence. The stock currently holds an average "Hold" rating with an average target price of $3.52 from analysts.
Canaccord Genuity Group Has Lowered Expectations for Definitive Healthcare (NASDAQ:DH) Stock Price
Canaccord Genuity Group has reduced its price target for Definitive Healthcare (NASDAQ:DH) from $4.00 to $3.00, maintaining a "hold" rating after the company lowered its Q1 and FY 2026 guidance. This news led to an 11.8% drop in shares to $1.24, despite some positive Q4 revenue and cash improvements. The consensus target price from analysts for DH is now $3.52, with institutional investors holding a significant portion of the stock.
Definitive Healthcare (DH) Quarterly Loss Highlights Ongoing Profitability Gap Despite Stable Revenue
Definitive Healthcare (DH) concluded FY 2025 with a Q4 revenue of US$61.5 million and a basic EPS loss of US$0.09, reflecting ongoing profitability challenges despite stable revenue figures. The company's net losses for the trailing twelve months reached US$138.9 million, significantly diverging from analyst expectations for future positive earnings. While the stock's low P/S ratio and discount to DCF fair value present a potential opportunity for long-term investors, the persistent losses and forecast revenue decline highlight significant risks.
Definitive Healthcare (DH) CEO granted 1.7M RSUs in new equity award
Definitive Healthcare Corp.'s CEO, Kevin Coop, has been granted 1,735,437 restricted stock units (RSUs) as a new equity award. These RSUs will vest over approximately three years, beginning with 25% on March 1, 2027, followed by quarterly vesting, contingent on his continued service. Following this grant, Coop beneficially owns 5,291,989 shares of Class A Common Stock.
Stephens Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $2.00
Stephens has lowered its price target for Definitive Healthcare (NASDAQ:DH) from $3.00 to $2.00, maintaining an "equal weight" rating, which still suggests a significant upside of 68% from its current share price. This adjustment comes amidst broader analyst sentiment reflecting a "Hold" rating for the stock, with an average target price of $3.66. The company's shares are currently trading near a one-year low, pressured by reduced Q1 and FY2026 guidance, GAAP losses, and weaker operating cash flow, despite some year-over-year cash improvement.
Definitive Healthcare (DH) CFO receives 733,301 RSU equity award in new grant
Definitive Healthcare Corp.'s CFO, Casey Heller, has been granted 733,301 restricted stock units (RSUs) of Class A common stock at $0.00 per share. These RSUs will vest 25% on March 1, 2027, with the remainder vesting in 6.25% increments every three months over the subsequent three years, contingent on Heller's continued employment. Following this award, Heller directly holds 2,007,322 shares or RSU-linked interests in the company.
[8-K] Definitive Healthcare Corp. Reports Material Event | DH SEC Filing - Form 8-K
Definitive Healthcare Corp. reported mixed financial results for Q4 and full year 2025, with revenue declines but improved profitability metrics and narrowed net losses. The company provided guidance for Q1 and full year 2026, anticipating further revenue decreases but maintaining focus on improving retention rates and increasing upsell/cross-sell activities. Despite ongoing goodwill impairments, Definitive Healthcare highlights solid underlying cash economics as it works towards better operational and financial performance.
Definitive Healthcare (DH) EVP corrects Form 3, discloses 4,045.654 shares
Benjamin Graboske, EVP and Chief Data Officer of Definitive Healthcare Corp. (DH), has filed an amended Form 3 to correct his initial statement of beneficial ownership. The amendment discloses 4,045.654 shares of Class A Common Stock that were mistakenly omitted from his original Form 3 and two subsequent Form 4 filings. This filing clarifies his direct beneficial ownership of these shares and does not represent a new transaction.
Definitive Healthcare (NASDAQ: DH) chair awarded 242,719 RSUs vesting 2027
Definitive Healthcare (NASDAQ: DH) executive chairman and 10% owner Jason Ronald Krantz was granted 242,719 restricted stock units (RSUs) on February 24, 2026, as reported in a SEC Form 4 filing. These RSUs vest 100% on March 1, 2027, contingent on his continued service to the company. Following this grant, Krantz directly holds 1,258,758 shares and indirectly 450,000 shares through DH Holdings.
Definitive Healthcare (DH) Earnings Transcript
Definitive Healthcare (DH) reported Q4 results that surpassed internal guidance for revenue and adjusted EBITDA, despite an overall 1% revenue decline year-over-year. The company restored claims data volumes and saw improvements in gross dollar retention, driven by enterprise accounts and growth in diversified and provider segments, though net dollar retention faced pressure from fewer upsell opportunities. Looking to 2026, the company forecasts continued revenue contraction but anticipates future improvement through product innovation, including GenAI integration, and ongoing strategic efforts to enhance customer retention and upsell capabilities.
Definitive Healthcare (DH) Earnings Transcript
Definitive Healthcare (DH) reported Q4 2025 financial results, exceeding revenue and adjusted EBITDA guidance despite a 1% year-over-year revenue decrease. The company successfully remediated industry-wide claims data disruptions, restored data volumes, and saw improvements in gross dollar retention, while net dollar retention declined due to fewer upsell opportunities. Looking ahead to 2026, the company anticipates continued revenue contraction but expects improvements in product innovation, especially with GenAI integration, and ongoing strategic investments to drive future growth and enhance customer retention.
Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Hold" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $3.94. The company's Q4 results showed stronger cash and steady revenue, but Q1 and FY-2026 EPS guidance fell below consensus estimates, leading to disappointment. Institutional selling in Q4 also contributed to near-term downward pressure on the stock, which trades near $1.40.
Definitive Healthcare (NASDAQ:DH) Updates FY 2026 Earnings Guidance
Definitive Healthcare (NASDAQ:DH) updated its FY 2026 earnings guidance, projecting EPS between $0.140 and $0.170 and revenue between $220.0 million and $226.0 million, both figures falling short of consensus analyst estimates. The company also set its Q1 2026 EPS guidance at $0.03. Following this announcement, the stock slipped to $1.40, trading near its 52-week low, while analysts maintain a consensus "Hold" rating with an average price target of $3.94 despite recent downgrades.
Definitive Healthcare (NASDAQ:DH) Releases Q1 2026 Earnings Guidance
Definitive Healthcare (NASDAQ:DH) has released its earnings guidance for Q1 2026 and updated its full-year 2026 outlook, projecting lower EPS and revenue than analyst consensus for the first quarter. Despite beating revenue estimates and meeting EPS for the most recent quarter, the company recorded a negative net margin of approximately -77.9%. Analysts currently rate the stock as "Hold" with a consensus target price of $3.94, while the stock trades near a 1-year low, and institutional investors hold a significant majority of its shares.
Healthcare data firm Definitive narrows Q4 net loss to $17.1M
Definitive Healthcare (NASDAQ: DH) reported its Q4 and full fiscal year 2025 financial results, with fourth-quarter revenue hitting $61.5 million and full-year revenue reaching $241.5 million. The company narrowed its Q4 net loss to $(17.1) million, significantly improving from $(84.7) million in Q4 2024, despite a full-year net loss of $(199.3) million largely due to goodwill impairments. Definitive Healthcare also provided guidance for fiscal year 2026, projecting revenue between $220.0 million and $226.0 million and adjusted EBITDA between $53.0 million and $58.0 million.
Large RSU grant to Definitive Healthcare (DH) Chief Legal Officer disclosed
Definitive Healthcare Corp. (DH) Chief Legal Officer Jonathan Paris was granted 481,505 restricted stock units (RSUs). These RSUs, which represent shares of Class A common stock, will vest 25% on March 1, 2027, and then 6.25% every three months over the subsequent three years, contingent on his continued employment. This transaction was disclosed in a Form 4 SEC filing on February 26, 2026, and increases his beneficial ownership to 902,854 shares.
Definitive Healthcare Corp. (NASDAQ:DH) Not Doing Enough For Some Investors As Its Shares Slump 26%
Definitive Healthcare Corp. (NASDAQ:DH) has seen its shares drop significantly, with a 26% decline in the last month and a 65% drop over the past year. Its low price-to-sales (P/S) ratio of 0.8x, compared to an industry average of 2.1x, reflects declining revenues and a negative growth outlook. Analysts forecast a 3.0% revenue decrease for the company while the industry is expected to grow by 12%, justifying the current low valuation but signaling potential difficulties for share price recovery.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of "Hold" from Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.94. The company recently beat its earnings and revenue estimates but still posted a negative net margin of 77.88%. Institutional investors hold approximately 98.67% of the company's stock, which currently trades around $2.32.
Definitive Healthcare Corp. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Definitive Healthcare Corp. (Nasdaq: DH) plans to release its financial results for the fourth quarter and full fiscal year ending December 31, 2025, on February 26, 2026, after the market closes. Following the announcement, the company will host a conference call and webcast at 5:00 PM ET to discuss the results and engage with investors. The article also provides details on Definitive Healthcare's recent financial performance, hedge fund activity, analyst ratings, and price targets.
Definitive Healthcare Corp. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Definitive Healthcare Corp. (Nasdaq: DH) plans to announce its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results, with replay options available until March 26, 2026. This announcement highlights their commitment to transparency and investor engagement, detailing recent hedge fund activity and analyst ratings, including a "Buy" rating from Stifel.
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Definitive Healthcare Corp (DH)
Analysts have issued neutral ratings for AMN Healthcare Services (AMN) and Definitive Healthcare Corp (DH), indicating neither bullish nor bearish sentiment. Needham analyst Ryan MacDonald maintained a Hold rating on Definitive Healthcare Corp, whose shares closed at $2.43. The consensus price target for Definitive Healthcare Corp is $3.71.
Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Drops By 23.2%
Definitive Healthcare Corp. (NASDAQ:DH) experienced a 23.2% drop in short interest in December, reaching 2,248,253 shares, representing 1.9% of its shares sold short and a short-interest ratio of 2.9 days. Analysts generally have a "Hold" rating with an average target price of $3.94, despite recent downgrades and lower price targets from several firms. The company's stock currently trades at $2.39, with a market capitalization of approximately $338 million, after reporting mixed financial results including beating quarterly EPS estimates but having a deeply negative net margin.
Definitive Healthcare Corp. Reports Q3 2025 Results
This article reports on Definitive Healthcare Corp.'s third-quarter 2025 financial results. It details the company's performance during this period.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of "Hold" from Analysts
Nine analysts currently give Definitive Healthcare Corp. (NASDAQ:DH) a consensus "Hold" rating, with an average 12-month price target of $3.94, compared to its recent share price of around $2.56. The company recently exceeded EPS and revenue estimates but continues to report a negative net margin. Institutional investors hold a significant majority (98.67%) of the stock.
Definitive Healthcare greatly expands all-payor medical and prescription claims coverage
Definitive Healthcare announced a significant expansion of its prescription and all-payor medical claims data within the Atlas Dataset, increasing coverage by over 60% for prescription claims and considerably for all-payor claims, including a nearly 20% rise in key areas like rare disease and oncology. This expansion, coupled with refined methodologies and increased patient overlap, provides clients with a more in-depth and holistic view of patient journeys to better understand market trends, inform product development, and optimize go-to-market strategies. The enhanced data aims to accelerate commercial success for organizations partnering with healthcare providers.
Definitive Healthcare to Present at the 28th Annual Needham Growth Conference
Definitive Healthcare (Nasdaq: DH) announced that its CFO, Casey Heller, will present at the 28th Annual Needham Growth Conference on January 14, 2026, at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the company's investor relations website, with a replay also accessible for a limited duration. Definitive Healthcare provides healthcare market data and analytics to help organizations make strategic decisions.
Definitive Healthcare (NASDAQ:DH) Cut to Buy at Wall Street Zen
Wall Street Zen downgraded Definitive Healthcare (NASDAQ:DH) from "strong-buy" to "buy" on Sunday, contributing to a mixed analyst consensus rating of "Hold" and a $3.94 price target for the stock. Despite this, the company exceeded Q3 EPS estimates and provided positive FY2025 guidance. Institutional investors hold a significant 98.7% of the shares, while the stock currently trades at $2.63 with a negative P/E ratio.
Definitive Healthcare (NASDAQ:DH) Upgraded by Wall Street Zen to Strong-Buy Rating
Definitive Healthcare (NASDAQ:DH) has been upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen. The company slightly beat its last quarter's EPS and revenue estimates, and analysts currently have a consensus "Hold" rating with an average price target of $3.94. Several institutional investors have recently acquired positions in DH.
Definitive Healthcare price target lowered to $3.50 from $5 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach has lowered the price target for Definitive Healthcare (DH) to $3.50 from $5, maintaining an Equal Weight rating. The analyst sees an attractive backdrop for alpha-generation opportunities in healthcare technology and providers for 2026. This adjustment comes amidst expectations of continued policy, reimbursement, and utilization headwinds for managed care stocks in 2025.
Definitive Healthcare price target lowered to $2.75 from $3 at Barclays
Barclays has lowered its price target for Definitive Healthcare to $2.75, down from the previous $3.00. The firm maintains an "Equalweight" rating on the stock.
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Hold" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $4.19. The company has a negative P/E ratio, trading below its moving averages, but recently beat quarterly EPS and revenue estimates. Institutional investors have made significant changes to their positions, with 98.67% of the stock owned by institutions.
Barclays Maintains Definitive Healthcare (DH) Underweight Recommendation
Barclays has maintained an "Underweight" recommendation for Definitive Healthcare (NasdaqGS:DH). Despite this, analysts forecast a 68.85% upside with an average one-year price target of $4.14/share. Institutional ownership shows significant holdings by Advent International and Goldman Sachs Group, though some firms have decreased their allocations.
Definitive Healthcare price target lowered to $2.75 from $3 at Barclays
Barclays has lowered its price target for Definitive Healthcare (DH) from $3 to $2.75, while maintaining an Equal Weight rating on the shares. This adjustment follows a transfer of coverage and reflects a neutral view on the U.S. healthcare technology and distribution industry. The firm is most optimistic about drug distributors but has a more mixed outlook for dental and healthcare information technology sectors.
Definitive Healthcare Corp. Forms Death Cross, Signaling Bearish Trend Ahead
Definitive Healthcare Corp. has experienced a Death Cross, a technical indicator suggesting a bearish trend, as its short-term moving average fell below its long-term moving average. The company's technical indicators, including MACD and Bollinger Bands, confirm a downward outlook. This event follows a significant decline in its stock performance over the past year, contrasting sharply with the S&P 500's gains.
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat By Investing.com
Definitive Healthcare (NASDAQ: DH) reported a 4% year-over-year revenue decline in Q3 2025, reaching $60 million, but exceeded analyst expectations with adjusted EPS of $0.07. Despite beating profitability estimates, the stock fell 2.57%, reflecting ongoing investor caution due to macroeconomic headwinds and a continued revenue growth challenge. The company projects a further 4-5% revenue decline for Q4 2025 but raised its full-year adjusted EBITDA guidance, while focusing on strategic initiatives to return to growth in 2026.
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat
Definitive Healthcare (NASDAQ:DH) reported Q3 2025 earnings, exceeding analyst expectations for EPS at $0.07 despite a 4% year-over-year revenue decline to $60 million. The company's stock fell 2.57% following the announcement, reflecting investor concerns over its growth trajectory amidst macroeconomic headwinds. Definitive Healthcare offered cautious guidance for Q4 2025 and reaffirmed its full-year outlook, emphasizing profitability and strategic initiatives for future growth.
